What is it about?
The issue of dialyzable and non-dialyzable beta-blockers for patients undergoing hemodialysis is gradually receiving attention. It is currently unknown whether the use of different types of beta-blockers has an impact on the prognosis of patients undergoing hemodialysis.
Featured Image
Photo by Ksenia Yakovleva on Unsplash
Why is it important?
We searched the database and identified relevant literature on the use of beta-blockers in hemodialysis patients. The prognosis was analyzed including major adverse cardiac events (MACE), acute myocardial infarction (AMI), and heart failure (HF).
Perspectives
I hope this article can provide more comprehensive evidence and confidence for clinical physicians regarding the use of beta-blockers in hemodialysis patients. I also expect that there will be more research on beta-blockers in hemodialysis patients in the future, providing more robust results.
Jui-Yi Chen
Chi-Mei Medical Center
Read the Original
This page is a summary of: Impact of type of dialyzable beta-blockers on subsequent risk of mortality in patients receiving dialysis: A systematic review and meta-analysis, PLoS ONE, December 2022, PLOS,
DOI: 10.1371/journal.pone.0279680.
You can read the full text:
Contributors
The following have contributed to this page
